Try our beta test site

Study to Assess the Safety and Effects of Cells Injected Intravitreal in Dry Macular Degeneration

This study has been withdrawn prior to enrollment.
Sponsor:
Information provided by (Responsible Party):
Bioheart, Inc.
ClinicalTrials.gov Identifier:
NCT02024269
First received: December 17, 2013
Last updated: September 15, 2015
Last verified: September 2015

December 17, 2013
September 15, 2015
December 2013
December 2016   (Final data collection date for primary outcome measure)
  • frequency and nature of adverse events [ Time Frame: 6 months ]
  • Visual Field analysis (10-2) [ Time Frame: 6 months ]
    Visual field testing can be performed clinically by keeping the subject's gaze fixed while presenting objects at various places within their visual field.
  • Visual Acuity Measurements [ Time Frame: 6 months ]
    Visual acuity is a measure of the spatial resolution of the visual processing system. VA is tested by requiring the person whose vision is being tested to identify so-called optotypes - stylized letters, Landolt rings or other patterns - on a chart from a set viewing distance.
Same as current
Complete list of historical versions of study NCT02024269 on ClinicalTrials.gov Archive Site
Intraocular pressure [ Time Frame: 6 months ]
Same as current
Not Provided
Not Provided
 
Study to Assess the Safety and Effects of Cells Injected Intravitreal in Dry Macular Degeneration
An Open-label, Non-Randomized, Multi-Center Study to Assess the Safety and Effects of Autologous Adipose-Derived Stromal Cells Injected Intravitreal in Dry Macular Degeneration
This will be an open-label, non-randomized multi-center study of adipose stem cell (ASC) implantation. ASCs will be derived from the patient's adipose or fat. Liposuction using local anesthesia and syringe collection will be performed to collect the adipose tissue specimen for subsequent processing to isolate the stem cells. The cells will be delivered via needle injection into the eye.
Not Provided
Interventional
Not Provided
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Dry Macular Degeneration
Biological: Adipose Derived Stem Cells
Experimental: Adipose Stem Cells
Intervention: Biological: Adipose Derived Stem Cells
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Withdrawn
0
June 2017
December 2016   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • Males and Females between Age 50 and 90 years
  • Patients with dry AMD
  • Visual acuity in the study eye <20200 (equal to or worse than 20/200)

Exclusion Criteria:

  • Females who are pregnant or nursing or females of childbearing potential who are unwilling to maintain contraceptive therapy for the duration of the study
  • Inability to undergo syringe liposuction procedure or have any medical problems that contraindicate the procedure.
  • Life expectancy < 6 months due to concomitant illnesses.
  • Vitrectomized eyes
  • Exposure to any investigational drug or procedure within 1 month prior to study entry or enrolled in a concurrent study that may confound results of this study.
  • Active infectious disease. . If patients have tested positive for HIV, HTLV, HBV, HCV, CMV (IgM > IgG) and/or syphilis, an expert will be consulted as to patient eligibility based on the patient's infectious status
  • Any illness which might affect a patient's survival over the follow-up period
  • Any illness which, in the Investigator's judgement, will interfere with the patient's ability to comply with the protocol, compromise patient safety, or interfere with the interpretation of the study results
  • Patients on chronic immunosuppressive transplant therapy
  • Patients with severe coagulation disorders
  • Systolic blood pressure (supine) ≤90 mmHg;
  • Resting heart rate > 100 bpm;
  • Active clinical infection being treated by antibiotics within one week of enrollment.
  • Cerebrovascular accident within 6 months prior to study entry
  • Known drug or alcohol dependence or any other factors which will interfere with the study conduct or interpretation of the results or who in the opinion of the investigator are not suitable to participate.
  • Severe COPD or severe asthma that would contraindicate surgery
  • History of cancer (other than non-melanoma skin cancer or in-situ cervical cancer) in the last two years.
  • Unwilling and/or not able to give written informed consent.
Sexes Eligible for Study: All
50 Years to 90 Years   (Adult, Senior)
No
Contact information is only displayed when the study is recruiting subjects
United States
 
 
NCT02024269
ADI-US-AMD-001
Not Provided
Not Provided
Not Provided
Not Provided
Bioheart, Inc.
Bioheart, Inc.
Not Provided
Not Provided
Bioheart, Inc.
September 2015

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP